![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TPRKB |
Gene summary for TPRKB |
![]() |
Gene information | Species | Human | Gene symbol | TPRKB | Gene ID | 51002 |
Gene name | TP53RK binding protein | |
Gene Alias | CGI-121 | |
Cytomap | 2p13.1 | |
Gene Type | protein-coding | GO ID | GO:0000722 | UniProtAcc | Q9Y3C4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51002 | TPRKB | LZE2T | Human | Esophagus | ESCC | 1.52e-03 | 7.64e-01 | 0.082 |
51002 | TPRKB | LZE4T | Human | Esophagus | ESCC | 6.77e-12 | 4.31e-01 | 0.0811 |
51002 | TPRKB | LZE7T | Human | Esophagus | ESCC | 7.90e-05 | 3.84e-01 | 0.0667 |
51002 | TPRKB | LZE8T | Human | Esophagus | ESCC | 2.52e-04 | 1.11e-01 | 0.067 |
51002 | TPRKB | LZE20T | Human | Esophagus | ESCC | 6.05e-03 | 7.63e-02 | 0.0662 |
51002 | TPRKB | LZE22T | Human | Esophagus | ESCC | 1.31e-04 | 3.03e-01 | 0.068 |
51002 | TPRKB | LZE24T | Human | Esophagus | ESCC | 1.56e-23 | 5.39e-01 | 0.0596 |
51002 | TPRKB | LZE21T | Human | Esophagus | ESCC | 1.77e-03 | 4.21e-01 | 0.0655 |
51002 | TPRKB | LZE6T | Human | Esophagus | ESCC | 3.36e-09 | 5.90e-01 | 0.0845 |
51002 | TPRKB | P1T-E | Human | Esophagus | ESCC | 2.89e-05 | 3.49e-01 | 0.0875 |
51002 | TPRKB | P2T-E | Human | Esophagus | ESCC | 2.47e-30 | 7.34e-01 | 0.1177 |
51002 | TPRKB | P4T-E | Human | Esophagus | ESCC | 4.82e-56 | 1.42e+00 | 0.1323 |
51002 | TPRKB | P5T-E | Human | Esophagus | ESCC | 1.41e-45 | 8.21e-01 | 0.1327 |
51002 | TPRKB | P8T-E | Human | Esophagus | ESCC | 1.22e-24 | 4.68e-01 | 0.0889 |
51002 | TPRKB | P9T-E | Human | Esophagus | ESCC | 9.16e-25 | 5.03e-01 | 0.1131 |
51002 | TPRKB | P10T-E | Human | Esophagus | ESCC | 1.86e-60 | 1.15e+00 | 0.116 |
51002 | TPRKB | P11T-E | Human | Esophagus | ESCC | 2.84e-18 | 5.52e-01 | 0.1426 |
51002 | TPRKB | P12T-E | Human | Esophagus | ESCC | 2.60e-35 | 6.40e-01 | 0.1122 |
51002 | TPRKB | P15T-E | Human | Esophagus | ESCC | 1.39e-33 | 6.65e-01 | 0.1149 |
51002 | TPRKB | P16T-E | Human | Esophagus | ESCC | 6.39e-29 | 5.31e-01 | 0.1153 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00322001 | Liver | HCC | telomere organization | 86/7958 | 159/18723 | 2.06e-03 | 1.04e-02 | 86 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:000072316 | Oral cavity | OSCC | telomere maintenance | 85/7305 | 131/18723 | 1.72e-09 | 4.09e-08 | 85 |
GO:00080332 | Oral cavity | OSCC | tRNA processing | 78/7305 | 127/18723 | 2.56e-07 | 4.00e-06 | 78 |
GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
GO:00064001 | Oral cavity | OSCC | tRNA modification | 53/7305 | 90/18723 | 1.04e-04 | 7.70e-04 | 53 |
GO:00322006 | Oral cavity | OSCC | telomere organization | 85/7305 | 159/18723 | 1.47e-04 | 1.04e-03 | 85 |
GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:000072317 | Oral cavity | LP | telomere maintenance | 59/4623 | 131/18723 | 2.88e-07 | 8.56e-06 | 59 |
GO:003220013 | Oral cavity | LP | telomere organization | 59/4623 | 159/18723 | 3.21e-04 | 3.25e-03 | 59 |
GO:00080331 | Oral cavity | LP | tRNA processing | 44/4623 | 127/18723 | 7.50e-03 | 4.15e-02 | 44 |
GO:000072314 | Prostate | BPH | telomere maintenance | 52/3107 | 131/18723 | 2.27e-10 | 1.23e-08 | 52 |
GO:00322005 | Prostate | BPH | telomere organization | 52/3107 | 159/18723 | 4.40e-07 | 8.92e-06 | 52 |
GO:00344708 | Prostate | BPH | ncRNA processing | 84/3107 | 395/18723 | 8.44e-03 | 3.64e-02 | 84 |
GO:000072315 | Prostate | Tumor | telomere maintenance | 52/3246 | 131/18723 | 1.13e-09 | 5.43e-08 | 52 |
GO:003220012 | Prostate | Tumor | telomere organization | 52/3246 | 159/18723 | 1.73e-06 | 3.05e-05 | 52 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TPRKB | SNV | Missense_Mutation | c.306C>G | p.His102Gln | p.H102Q | Q9Y3C4 | protein_coding | deleterious(0.02) | probably_damaging(0.967) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TPRKB | SNV | Missense_Mutation | c.433C>G | p.Leu145Val | p.L145V | Q9Y3C4 | protein_coding | tolerated(0.09) | possibly_damaging(0.482) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
TPRKB | SNV | Missense_Mutation | novel | c.593N>T | p.Gly198Val | p.G198V | Q9Y3C4 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TPRKB | SNV | Missense_Mutation | c.592N>A | p.Gly198Arg | p.G198R | Q9Y3C4 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-DM-A28C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TPRKB | SNV | Missense_Mutation | novel | c.404N>G | p.Phe135Cys | p.F135C | Q9Y3C4 | protein_coding | deleterious(0.04) | possibly_damaging(0.56) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TPRKB | SNV | Missense_Mutation | novel | c.625T>C | p.Ser209Pro | p.S209P | Q9Y3C4 | protein_coding | deleterious(0.01) | possibly_damaging(0.83) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TPRKB | SNV | Missense_Mutation | novel | c.351A>C | p.Glu117Asp | p.E117D | Q9Y3C4 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TPRKB | SNV | Missense_Mutation | novel | c.634G>T | p.Asp212Tyr | p.D212Y | Q9Y3C4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
TPRKB | SNV | Missense_Mutation | rs368782517 | c.140N>C | p.Val47Ala | p.V47A | Q9Y3C4 | protein_coding | deleterious(0.01) | benign(0.164) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
TPRKB | SNV | Missense_Mutation | novel | c.335G>T | p.Arg112Ile | p.R112I | Q9Y3C4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |